Celladon Corp (CLDN) 12.64 $CLDN
Celladon Corporation Secures $25 Million Credit Facility From Hercules Growth Capital
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders. The credit facility provides for up to $25 million of loans.
Celladon to Report Second Quarter 2014 Results on August 7, 2014
GlobeNewswire - Wed Jul 30, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014. The company will also hold a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific on Thursday, August 7, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Celladon Corporation Announces In-License of Stem Cell Factor Development Program
GlobeNewswire - Mon Jul 21, 6:09AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells.
Celadon Group Set to Join the S&P SmallCap 600
PR Newswire - Mon Jul 14, 4:49PM CDT
Celadon Group Inc. (NYSE: CGI) will replace Cbeyond Inc. (NASD: CBEY) in the S&P SmallCap 600 after the close of trading on Thursday, July 17. Birch Communications Inc. is acquiring Cbeyond in a deal expected to be completed soon.
Celadon Group Announces Dates for Earnings Release and Conference Call
PR Newswire - Fri Jul 11, 4:06PM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2014 fourth quarter and fiscal year end results on Wednesday, August 6 after the close of the market. A conference call to discuss the fourth quarter and fiscal year end results will be held Thursday, August 7 at 11:00 a.m. Eastern Time.
Celladon Corporation Announces New Clinical Development Initiatives for MYDICAR(R)
GlobeNewswire - Mon Jul 07, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Partnerships, NAV Updates, New Contracts, and Residential Project Launch - Analyst Notes on Pace, Caledonia, Kentz, Murray and Persimmon
PR Newswire Europe - Thu Jul 03, 12:11AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
Financial Guidance, Appointments, Board Elections, and Technical Updates - Analyst Notes on Amedisys, Dyax, TearLab, Celladon and Alphatec
PR Newswire - Wed Jul 02, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amedisys Inc. (NASDAQ: AMED), Dyax Corp. (NASDAQ: DYAX), TearLab Corp. (NASDAQ: TEAR), Celladon Corp. (NASDAQ: CLDN) and Alphatec Holdings Inc. (NASDAQ: ATEC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4350-100free.
Celladon Corporation (CLDN) Jumps: Stock Rises 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:21AM CDT
Celladon Corporation (CLDN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 30, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Winning Global Equity Mandate, Strategic Partnership, Sale of Investment, Upcoming Event, and NAV Report - Analyst Notes on Henderson, Pace, Caledonia, Kentz and Murray International Trust
PR Newswire Europe - Wed Jun 11, 8:07AM CDT
LONDON, June 10, 2014 /PRNewswire/ --
Pulmonary Arterial Hypertension - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfk67l/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - United Therapeutics Corporation - Merck & Co., Inc. - Novartis AG - Actelion Ltd - Nippon Shinyaku Co., Ltd. - Toray Industries, Inc. - Celladon Corporation - Arena Pharmaceuticals, Inc. - Cytokinetics, Incorporated - HanAll Biopharma Co., Ltd. - Pluristem Therapeutics Inc. - Proteo, Inc. - Ironwood Pharmaceuticals, Inc. - Aires Pharmaceuticals, Inc. - Cardioxyl Pharmaceuticals, Inc. - Therametrics holding AG - PhaseBio Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Reata Pharmaceuticals, Inc. - Polyphor Ltd. - Lacer, S.A. - Ikaria Inc. - Bial - Portela & Ca, S.A. - Northern Therapeutics, Inc. - miRagen Therapeutics, Inc. - PharmaIN Corporation - Tarix Pharmaceuticals LTD. - EGEN, Inc. - Corridor Pharmaceuticals Inc. - Sagene Pharmaceuticals, Inc. - Mezzion Pharma Co. Ltd. - Sinoxa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/pfk67l/pulmonary
Celladon Corporation Appoints Elizabeth E. Reed General Counsel
GlobeNewswire - Mon Jun 09, 6:12AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has appointed Elizabeth E. Reed as Vice President and General Counsel.
Celladon Corporation Secures $25 Million Credit Facility From Hercules Growth Capital
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders. The credit facility provides for up to $25 million of loans.
Celladon to Report Second Quarter 2014 Results on August 7, 2014
GlobeNewswire - Wed Jul 30, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it will report its results for the second quarter ended June 30, 2014 on Thursday, August 7, 2014. The company will also hold a live investor conference call and webcast at 8:30am Eastern/5:30am Pacific on Thursday, August 7, 2014.
Nasdaq stocks posting largest percentage decreases
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Celladon Corporation Announces In-License of Stem Cell Factor Development Program
GlobeNewswire - Mon Jul 21, 6:09AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation today announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to cell migration, proliferation, and survival of cardiac stem cells.
Celadon Group Set to Join the S&P SmallCap 600
PR Newswire - Mon Jul 14, 4:49PM CDT
Celadon Group Inc. (NYSE: CGI) will replace Cbeyond Inc. (NASD: CBEY) in the S&P SmallCap 600 after the close of trading on Thursday, July 17. Birch Communications Inc. is acquiring Cbeyond in a deal expected to be completed soon.
Celadon Group Announces Dates for Earnings Release and Conference Call
PR Newswire - Fri Jul 11, 4:06PM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2014 fourth quarter and fiscal year end results on Wednesday, August 6 after the close of the market. A conference call to discuss the fourth quarter and fiscal year end results will be held Thursday, August 7 at 11:00 a.m. Eastern Time.
Celladon Corporation Announces New Clinical Development Initiatives for MYDICAR(R)
GlobeNewswire - Mon Jul 07, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has launched two new clinical development initiatives for MYDICAR(R), its lead product candidate, in patients with end-stage renal disease (ESRD) undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis, and in advanced heart failure patients with systolic dysfunction that were previously excluded from MYDICAR trials due to pre-existing levels of neutralizing antibodies.
Partnerships, NAV Updates, New Contracts, and Residential Project Launch - Analyst Notes on Pace, Caledonia, Kentz, Murray and Persimmon
PR Newswire Europe - Thu Jul 03, 12:11AM CDT
LONDON, July 3, 2014 /PRNewswire/ --
Financial Guidance, Appointments, Board Elections, and Technical Updates - Analyst Notes on Amedisys, Dyax, TearLab, Celladon and Alphatec
PR Newswire - Wed Jul 02, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Amedisys Inc. (NASDAQ: AMED), Dyax Corp. (NASDAQ: DYAX), TearLab Corp. (NASDAQ: TEAR), Celladon Corp. (NASDAQ: CLDN) and Alphatec Holdings Inc. (NASDAQ: ATEC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4350-100free.
Celladon Corporation (CLDN) Jumps: Stock Rises 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:21AM CDT
Celladon Corporation (CLDN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
4 Stocks Breaking Out on Big Volume
at The Street - Mon Jun 30, 5:00AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Winning Global Equity Mandate, Strategic Partnership, Sale of Investment, Upcoming Event, and NAV Report - Analyst Notes on Henderson, Pace, Caledonia, Kentz and Murray International Trust
PR Newswire Europe - Wed Jun 11, 8:07AM CDT
LONDON, June 10, 2014 /PRNewswire/ --
Pulmonary Arterial Hypertension - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pfk67l/pulmonary) has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - United Therapeutics Corporation - Merck & Co., Inc. - Novartis AG - Actelion Ltd - Nippon Shinyaku Co., Ltd. - Toray Industries, Inc. - Celladon Corporation - Arena Pharmaceuticals, Inc. - Cytokinetics, Incorporated - HanAll Biopharma Co., Ltd. - Pluristem Therapeutics Inc. - Proteo, Inc. - Ironwood Pharmaceuticals, Inc. - Aires Pharmaceuticals, Inc. - Cardioxyl Pharmaceuticals, Inc. - Therametrics holding AG - PhaseBio Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Reata Pharmaceuticals, Inc. - Polyphor Ltd. - Lacer, S.A. - Ikaria Inc. - Bial - Portela & Ca, S.A. - Northern Therapeutics, Inc. - miRagen Therapeutics, Inc. - PharmaIN Corporation - Tarix Pharmaceuticals LTD. - EGEN, Inc. - Corridor Pharmaceuticals Inc. - Sagene Pharmaceuticals, Inc. - Mezzion Pharma Co. Ltd. - Sinoxa Pharma GmbH For more information visit http://www.researchandmarkets.com/research/pfk67l/pulmonary
Celladon Corporation Appoints Elizabeth E. Reed General Counsel
GlobeNewswire - Mon Jun 09, 6:12AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has appointed Elizabeth E. Reed as Vice President and General Counsel.
